Ibrance vs Calquence
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Ibrance | US Calquence | |
|---|---|---|
| Generic name | palbociclib | acalabrutinib |
| Drug class | CDK4/6 Inhibitor | BTK Inhibitor |
| Treats | HR+/HER2- breast cancer | Chronic lymphocytic leukemia and mantle cell lymphoma |
| Category | Oncology | Oncology |
| Manufacturer | Pfizer | AstraZeneca |
| Year approved | 2015 | 2017 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $80M | — |
| Common side effects | Low white blood cell count, Infections, Fatigue, Nausea | Headache, Diarrhea, Bruising and bleeding, Infections |
Calquence
Frequently asked questions
Is Ibrance or Calquence better?
Neither is universally "better." Ibrance (palbociclib) and Calquence (acalabrutinib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Ibrance and Calquence?
Ibrance is a CDK4/6 Inhibitor made by Pfizer, while Calquence is a BTK Inhibitor made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Ibrance has the larger estimated TV advertising budget of the two.